Scientists probe tumor metabolism to outsmart immunotherapy resistance in melanoma

NCT ID NCT05307289

Recruiting now Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Nice Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is investigating why some melanomas stop responding to immunotherapy. Researchers will take biopsies from 20 patients with advanced melanoma before and after treatment to see how tumor metabolism changes. The goal is to understand resistance mechanisms and find new ways to target cancer cells without harming immune cells.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this research could point toward new ways to overcome immunotherapy resistance in melanoma, potentially leading to more effective treatments.
What could go wrong: This is a small, early-stage observational study with only 20 participants. It is not testing a treatment, so it may not directly lead to new therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CUTANEOUS MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cutaneous melanoma melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MELANOMA (SKIN)

Contacts and locations

Locations

CHU de Nice
RECRUITING

Nice, Alpes-maritimes, 06001, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.